PUBLISHER: DelveInsight | PRODUCT CODE: 1226666
PUBLISHER: DelveInsight | PRODUCT CODE: 1226666
"Inavolisib Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Inavolisib for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Inavolisib for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the Inavolisib for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Inavolisib market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.
Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.
The company is currently investigating a Phase II/III trial to evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor (HR+, HER2- locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Inavolisib Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Inavolisib in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of Inavolisib in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions